{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-113623","form_type":"8-K","ticker":"ISPC","cik":"0001558569","company_name":"iSpecimen Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.506127+00:00","generated_at":"2026-06-09T00:11:35.433114+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"iSpecimen Q3 revenue $2.8M (+8% YoY, +75% sequential); net loss $2.1M; cash burn persists","bullets":["Revenue of $2.8M for Q3 2023 vs $2.6M in Q3 2022; sequential growth of 75% from $1.6M in Q2 2023.","Net loss of $2.1M ($0.23 per share) improved from $3.1M loss ($0.35) in Q3 2022; 9-month loss $8.0M ($0.89).","Cash and securities totaled $5.6M as of Sept 30, 2023, down from $15.3M at Dec 31, 2022; cash burn $9.7M in 9M2023.","Unique customer organizations reached 603 (+26% YoY); registered users 7,326 (+15% YoY); supplier orgs 234.","CEO targets cash flow neutral by year end; launched Next-Day Quote and Cancer Sequencing Procurement Program."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-113623","json":"https://secwatch.observer/filing/0001104659-23-113623.json","markdown":"https://secwatch.observer/filing/0001104659-23-113623.md","text":"https://secwatch.observer/filing/0001104659-23-113623.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000110465923113623/0001104659-23-113623-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000110465923113623/tm2329606d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:11:35.433114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"021b3db9e1d5a35ed437cc9eafafa26e93846089","claim":"iSpecimen Inc. reported the three and nine month periods ended September 30, 2023 results: revenue $2.8 million for the three-month period ended September 30, 2023, net income $2.1 million, or $(0.23) per share, EPS $(0.23) per share.","evidence_excerpt":"iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and nine month periods ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000110465923113623/0001104659-23-113623-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine month periods ended September 30, 2023"},{"label":"Revenue","value":"$2.8 million for the three-month period ended September 30, 2023"},{"label":"Net income","value":"$2.1 million, or $(0.23) per share"},{"label":"EPS","value":"$(0.23) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}